<DOC>
	<DOCNO>NCT00596037</DOCNO>
	<brief_summary>The objective rollover study evaluate long term ( 1 year ) safety new weekly administer growth hormone preparation adult growth hormone deficiency treat experimental preparation study BPLG-005 . In addition , change efficacy endpoints BPLG-005 prolonged treatment evaluate . Additional efficacy safety data experimental preparation obtain switch-over patient .</brief_summary>
	<brief_title>Treatment Adults With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Patients ( male female ) complete Visit 8 precede main study ( BPLG005 ) willing continue participation extension study If female , woman childbearing potential use reliable method contraception willing use throughout study . A negative urine pregnancy test Visit 0 require female childbearing potential Written inform consent patient Evidence active malignancy growth previously stable tumor Benign intracranial hypertension Clinically significant respiratory , cardiac , hepatic , renal , neuromuscular disease Noncompliance medication , uncooperativeness drug abuse BPLG005 study Patients able comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>23 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Growth hormone Deficiency</keyword>
</DOC>